Insulin Regimens: Hitting Glycemia Targets

Similar documents
Insulin Prior Authorization with optional Quantity Limit Program Summary

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols. Askiel Bruno, MD, MS Protocol PI

Disclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2

Type I Type II Insulin Resistance

Type 2 Diabetes Mellitus Insulin Therapy 2012

Inpatient Diabetes Management: The Slippery Slope of Sliding Scale Insulin

Adjusting Insulin Doses

Nph insulin conversion to lantus

INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE

Learning Objectives. Perioperative SWEET Success

8/21/2017 UNRAVELING THE CROWED INSULIN SCENE. A Practical Overview of Insulin Focusing on New Insulin Preparations

Converting lantus to humalog 75 25

Insulin Basics. Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology

Comprehensive Diabetes Treatment

4/16/2018. Flexible Intensive Insulin Therapy (FIIT) in People with Type 2 Diabetes: A Viable Option. Disclosures. Outline. No financial disclosures

ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:

INSULIN OVERVIEW. Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro min. 3-5 hrs min.

INSULIN 101: When, How and What

In-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University

Mixed Insulins Pick Me

Newer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

Insulin analogues Das PP, Datta PG

APPENDIX American Diabetes Association. Published online at

Diabetes in Pregnancy

ANNUAL MEETING 2 #FSHP2017

Management of Diabetes New Concepts New Devices New Medications. Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth

Basal Bolus Insulin Therapy Frequently Asked Questions

Diabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE

Objectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17

Lantus to levemir conversion

Inpatient Glycemic Management:

Initiating Injectable Therapy in Type 2 Diabetes

Short-acting insulins. Biphasic insulins. Intermediate- and long-acting insulins

Poll Question 2. Special Boot Camp Workshop Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services.

Thursday School 2010 Management of Inpatient Diabetes and Hyperglycemia and Quality Improvement Efforts

Pediatric Diabetes Update Fran R. Cogen, MD, CDE Professor of Pediatrics Director, Diabetes Services

MANAGEMENT OF TYPE 1 DIABETES MELLITUS

Diabetic Ketoacidosis

Lantus levemir conversion

New Therapies for Diabetes Management: Hope or Headache?

Exogenous Insulin in type 2 DM

Background: Brief review of epidemiology, diagnosis, classification and pathophysiology of diabetes mellistus.

Optimizing Care of the Inpatient with Hyperglycemia and Diabetes: Case Studies in Action

Pharmacy Plan Guidance

AACN PCCN Review. Endocrine

Glycemic Control Insulin In The Hospital Setting

Tips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital

Important Stuff. Basal Bolus What Adjustments? Pt weighs 80kg

Type 1 Diabetes-Pathophysiology, Diagnosis, and Long-Term Complications. Alejandro J de la Torre Pediatric Endocrinology 10/17/2014

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

Initiation and Titration of Insulin in Diabetes Mellitus Type 2

Diabetes: Inpatient Glucose control

Objectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment

Glucose Management in Noncritical Hospitalized Patients

These Aren t Your Average Rookies: A Primer on New and Emerging Insulins. Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP

Glucose Management in the ICU: The Role of the Pharmacist

Providing Stability to an Unstable Disease

Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy

Initiation and Adjustment of Insulin Regimens for Type 2 Diabetes

Transition of Care in Hospitalized Patients with Hyperglycemia and Diabetes

Basal-Bolus Insulin Therapy. Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January

INSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد

Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary

January 7, 5:00 p.m. EST

Insulin Initiation and Intensification. Disclosure. Objectives

Insulin Analogs & Premixed Insulin Analogs

Update on Insulin-based Agents for T2D

Insulin 10/11/17. Disclosures. Objectives. Speaker and Consultant for Jansen and Healthscripts Speaker and Consultant for Boehringer Ingelheim (BI)

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

Conversion from lantus to tresiba

Module 5. Understanding Insulin Therapy

Insulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products

Insulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products

第十五章. Diabetes Mellitus

The ABCs of MDI: Gaining a working knowledge of Multiple Daily Injection insulin therapy. Today s Presenter

Diabetic Emergencies DKA, HHS, Hypoglycemia. Disclosure. Learning Objectives

Diabetes Head to Toe May 31, 2017

4/10/2015. Foundations to Managing Inpatient Hyperglycemia. Learning Objectives

9/16/2013. No Conflict of Interest to Disclose

8/13/2016. Insulin Basics. Rapid-Acting Insulin Analogs. Current Insulin Products and Pens. Basal Insulin Analogs. History of Insulin Therapy

Timely!Insulinization In!Type!2! Diabetes,!When!and!How

Inpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, :30 a.m. 11:15 a.m.

Degludec lantus conversion

UKPDS: Over Time, Need for Exogenous Insulin Increases

Insulin Management. By Susan Henry Diabetes Specialist Nurse

Inpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, :30 a.m. 11:15 a.m.

Αναγκαιότητα και τρόπος ρύθμισης του διαβήτη στους νοσηλευόμενους ασθενείς

Martin J Stevens MD, FRCP, Endocrinologist and Professor of Medicine

HYPERGLYCEMIA MANAGEMENT PROTOCOL A BASAL/BOLUS REGIMEN. Kacy Aderhold, MSN, APRN-CNS, CMSRN

2018 Diabetes Summit Managing Diabetes: An Art and a Science

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville

Insulin therapy in gestational diabetes mellitus

Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate

INSULIN ALLERGY OBJECTIVES CASE OF DL

DEMYSTIFYING INSULIN THERAPY

Diana McNeill MD, FACP Professor of Medicine Duke University Medical Center. Disclosures

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

CANDY Camp Application

Transcription:

Insulin Regimens: Hitting Glycemia Targets Grant Kelley MD March 1 st, 2018

Faculty Disclosure: Financial relationships with commercial interests None

Overview Mortality and Morbidity Insulin and Insulin analogs. Target Glucose Four steps to calculate insulin regimen 1. Total Daily Dose (TDD) 2. Basal Insulin 3. Nutritional Insulin 4. Correction Insulin New SQ Insulin Order Set Cases 70 kg DM2 outpatient Glyburide and Januvia with A1c 7 140 kg DM2 outpatient 90U 70/30 am and 45U 70/30 hs with A1c 8 100 kg DM2 outpatient 80U Lantus and Metformin with A1c10 70kg DM1 outpatient 21L and sliding scale with meals with A1c7 60kg DM1 insulin pump basal unconscious after CVA.

Diabetes Type 1 Type 2 Onset Sudden Gradual Age Onset Children/Adolescent Adult Body Habitus Thin/Normal Obese Ketoacidosis Risk Common Rare Autoantibody Usually present Absent Endogenous Insulin Low or absent Normal, decreased, increased Genetic concordance identical twins 50% 90% Prevalence 10% 90% Treatment Insulin Oral agents and Insulin 1) Basal Insulin Absolute Requirement in DM1 2) Stop Oral Agents in DM2

Morbidity and Mortality and Hypoglycemia Increase in inpatient mortality risk: 41-70 mg/dl adjusted odds ratio (OR) 1.62 <40 mg/dl adjusted odds ratio (OR) 2.05 Increase LOS cw >70mg/dL group: 41-70 mg/dl 1.51 fold <40 mg/dl 2.33 fold Diabetes Med. 12:e445-8, 2012

Morbidity and Hyperglycemia 1. Fluid and electrolyte abnormalities secondary to osmotic diuresis 2. Decreased WBC function 3. Delayed gastric emptying 4. Increased surgical complications including: Glc > 220 mg/dl - relative risk postop nosocomial infection 5.7 fold. Glc 207-227 mg/dl - relative odds of wound infection to 1.17. Glc >253 mg/dl - relative odds of wound infection to 1.78-1.86. 5. LOS with fluctuating (glucose <60 or >250 mg/dl) vs control (glucose 60-250 mg/dl). http://www.endotext.org/diabetes/diabetes19/diabetesframe19.htm

Insulin Signaling http://www.cellsignal.com/reference/pathway/insulin_receptor.html

Hyperglycemia and Poor Hospital Outcome Metabolic stress response stress hormones and peptides Glucose Insulin Reactive O2 species Immune dysfunction Infection dissemination FFA Ketones Lactate Cellular injury/apoptosis Inflammation Tissue damage Altered tissue wound repair Clement et al, Diabetes Care 27:553-591, 2004 Prolonged hospital stay Disability / Death Transcription factors Secondary mediators

Target St Joseph s Hospital 121-170 (80-200) mg/dl Outpatient Fasting 80-130 mg/dl -SICU/MICU 140-200. Ann Intern Med 154:260-267, 2011 -Intensive Insulin Therapy in Hospitalized Patients: A Systemic Review. Ann Intern Med 154:268-282, 2011 -Standards of Medical Care in Diabetes 2013. DIABETES CARE, VOLUME 36, SUPPLEMENT 1, JANUARY 2013 -http://www.endotext.org/diabetes/diabetes19/diabetesframe19.html

INSULINS

INSULIN HISTORICAL PERSPECTIVE Discovery: 1921-22: Banting, Best, Macleod, Campbell, and Fletcher discovered insulin Nobel Prizes: 1923: Banting and Macleod Nobel Prize in Physiology or Medicine:. 1958: Frederick Sanger Nobel Prize sequencing insulin. 1969: Dorothy Hodgkin Nobel Prize tertiary structure X-Ray diffraction. 1977: Rosalyn Yalow Nobel Prize radioimmunoassay for insulin Davidson, Clinical Diabetes Mellitus; Kahn and Weir Joslin's Diabetes Mellitus

Insulin Beef and Pork Insulin: -1920s - 1980s insulin purified from beef or pork pancreata 1L insulin from pig pancreata shown Human Recombinant Insulin: -1980s recombinant DNA technology -produce human insulin in Saccharomyces cerevisiae or E coli. Human Insulin Analogs: -2000s recombinant DNA technology -development of human insulin analogs. -engineered to alter pharmacokinetics absorption from subcutaneous tissue binding to proteins. http://ringthebolus.blogspot.com/2010/12/history-of-insulin-part-2.html classroom.sdmesa.net/eschmid/lab7-biol210.htm

(Lantus) (Levemir) Degludec (Triceba) Des-B30 De Glu (deleted Glu) +16C diacid dec (hexadecanedioic acid added) http://diabetesmanager.pbworks.com/insulin%2b-%2bpharmacology%252c%2btypes%2bof%2bregimens%252c%2band%2badjustments

http://diabetesmanager.pbworks.com/insulin%2b-%2bpharmacology%252c%2btypes%2bof%2bregimens%252c%2band%2badjustments

Regular (1921-22) human, crystalline zinc insulins. Insulin preparations NPH (neutral protamine Hagedorn; 1936) protamine complex to delay absorption. Rapid acting analogs: aspart (Novolog), glulisine (Apidra) and lispro (Humalog) modified to decrease heximer and dimer formation. Long acting analogs: glargine (Lantus, Toujeo 300U/mL, Basaglar), detemir (Levemir) and degludec (Tiseba) modified to slow absorption kinectics: -glargine, degludec soluble at ph 4.0 but precipitates at physiologic ph upon SC injection. -detemir: binds albumin through its engineered fatty acid moiety. Mixtures: e.g. Humulin 70/30, Humalog 75/25

Insulin Profiles Toujeo (U300 glargine) Basaglar (glargine) Triseba (degludec ) http://www.endotext.org/diabetes/diabetes20/ch01s06.html

Insulin Profiles: Best Insulin to Cover Glucose 1. Basal 2. Nutritional 3. Correction Insulin Effect NPH Detemir (Levemir) Glargine (Lantus) Regular Lispro (Humalog) Aspart (Novolog) Glulisine (Apidra) Inhaled insulin 0 6 12 18 24 Time (hours) Society of Hospital Medicine

Insulin Profiles: Stacking Insulin given before a previous dose is gone will stack onto the previous dose Insulin Effect 0 6 12 18 24 Time (hours) Society of Hospital Medicine

Insulin Profiles Avoid Mixtures In Hospital: 70/30; 75/25

INSULIN REGIMEN: TOTAL DAILY DOSE (TDD)

Basal Bolus Insulin Regimen Basal Insulin: Insulin to cover glucose produced by the liver/kidneys Bolus Insulin: Nutritional + Correction Nutritional: insulin to cover meal carbs. Correction: insulin to correct blood glucose to target.

Basal, Bolus, and Correction Insulin 400 Glucose and Insulin Profiles Breakfast Lunch Dinner Basal Insulin Nutritional Insulin Correction Insulin Glucose (mg/dl) 300 200 100 0 0 600 1200 1800 2400

Physiologic Insulin Secretion: Basal/Bolus Concept Insulin (µu/ml) 50 25 0 Nutritional (Prandial) Insulin Basal Insulin Breakfast Lunch Supper Glucose (mg/dl) 150 100 50 0 Nutritional Glucose Basal Glucose 7 8 9 101112 1 2 3 4 5 6 7 8 9 A.M. P.M. Time of Day The 50/50 Rule

Four Steps to Calculate Basal Bolus Insulin Using Total Daily Dose 1. TDD (total daily dose): Daily insulin requirement. 2. Basal (~50% TDD): Insulin to cover glucose produced by the liver/kidneys. 3. Nutritional (~50% TDD): Insulin to cover meal carbs. 4. Correction (TDD dependent): Insulin to correct blood glucose to target.

Step 1) Calculate Total Daily Dose (TDD) 1) Preadmission Insulin: add insulin per day = TDD (best indication) beware of high doses of basal insulin (110 U Lantus no bolus) 2) Weight Based: Frail: Average: Resistant: 0.2-0.3U/kg/day (eg. thin, new DM1) (50kg=15U) 0.4-0.5U/kg/day (eg. new DM2) (70kg=35U) 0.6-0.7U/kg/day (eg. Obese DM2) (100kg=70U) 3) Insulin drip-based: add last 20h = TDD (careful with high rates) average rate last 4 hours x 20 = TDD ***Best educated guess use all available info! ***Average nondiabetic TDD ~30U.

Step 2) Calculate Basal Insulin 50/50 rule Basal insulin is ~ 50% of TDD. eg. TDD=36U/day then basal ~ 18U Lantus. Long acting insulin: Glargine (Lantus) (once a day) Detemir (Levemir) (once-twice a day) NPH (twice a day)

Advanced Calculation: Nutritional Calculate Nutritional Insulin Insulin Carbohydrate Ratio = 500 rule ~500/TDD = g Carb per U of insulin. e.g. TDD=180U/day 500/180 = 2.8 so 1U insulin required per 2.8 g Carb 60g Carbohydrate average ADA meal 60/2.8~20U Using Insulin, John Walsh et al, Torrey Pines Press

Step 3) Calculate Nutritional Insulin 50/50 rule Nutritional insulin is ~ 50% of TDD divided between 3 meals. eg. TDD=36U/day ~ 18/3=6U/meal. Rapid or Short acting insulin: Glulisine (Apidra) Aspart (Novolog) Lispro (Humalog) Regular (Novolin, Humulin)

Step 4) Calculate Correction Insulin Insulin required to correct hyperglycemia to target. Use Rapid or Short acting insulin. Dependent on sensitivity or TDD. Target Frail TDD<40 1U/50 Average 41-80 2U/50 81-120 3U/50 Obese >120 4U/50 121-170 0 0 0 0 171-220 1 2 3 4 221-270 2 4 6 8 271-320 3 6 9 12 321-370 4 8 12 16 371-420 5 10 15 20 >420 MD 6 12 18 24

Advanced Calculation: Correction Step 4) Correction Insulin Sensitivity = 1800 rule ~1800/TDD = mg/dl glc change per U insulin. e.g. TDD=180U/day 1800/180=10 so 1U insulin will drop glc 10mg/dl. To correct 300mg/dl / 10 = 30U Using Insulin, John Walsh et al, Torrey Pines Press

Grid Nutritional and Correction Insulin (Bolus)

Ordering SQ Insulin NEW SQ Insulin order set

Medication Section of New SC Insulin Order Set

Medication Section of New SC Insulin Order Set

MAR: SC Insulin Order Target 121-170

Daily Adjustments Monitor glucose levels daily Consideration for changing sensitivity Steroids Improving condition (sepsis, etc.) Increase or decrease TDD by 10-20% TDD 36 x 1.2 ~ 42 TDD 36 x 0.8 ~ 28

Daily Adjustments Evaluate Glucose Measurements: basal: fasting changes reflect basal insulin. -if fasting hs to am need more long-acting insulin. -if fasting hs to am need less long-acting insulin. -if fasting hs to am good. bolus (nutrition + correction): next premeal should correct to target.

Review Patient Glycemia and Insulin Administration

Review Patient Glycemia and Insulin Administration

DISCHARGE TOOLS

Add Nutritional Scale to AVS

Nutritional Scale Added to AVS

CASES

Case 1: Four Step Calculation 70 kg DM2 outpatient Glyburide and Januvia with A1c 7 1. TDD: 2. Basal: 3. Nutritional: 4. Correction: (no hm ins) or (0.3U/kg=21U) 10U Lantus 3U Humalog ac Built into order set The patient is made NPO and POC Glc have been 100-140mg/dL. How should the insulin dosing be changed?

Medication Section of New SC Insulin Order Set X 10 Units Lantus X

Case 2: Four Step Calculation 140 kg DM2 outpatient 90U 70/30 am and 45U 70/30 hs with A1c 8 1. TDD: 2. Basal: 3. Nutritional: 4. Correction: 108U (135Ux.8) or (0.7U/kg=98U) 54U Lantus 18U Humalog ac Built into order set The patient is made NPO and POC Glc have been 120-160mg/dL. How should the insulin dosing be changed?

X 54 Units Lantus X

Case 3: Four Step Calculation 100 kg DM2 outpatient 80U Lantus and Metformin with A1c10 1. TDD: 64U (80Ux.8) or (0.7U/kg=70U) 2. Basal: 32U Lantus 3. Nutritional: 10U Humalog ac 4. Correction: Built into order set

X 32 Units Lantus X

Case 3 part b: Four Step Calculation 100 kg DM2 outpatient 80U Lantus and Metformin with A1c10 1. TDD: 64U (80Ux.8) or (0.7U/kg=70U) 2. Basal: 32U Lantus 3. Nutritional: 10U Humalog ac 4. Correction: Built into order set POC Glc range from 200-300 mg/dl. What would you do? 1. TDD: 64x1.2=76; 64x1.1=70 2. Basal: 38U Lantus 3. Nutritional: 12U Humalog ac 4. Correction: Built into order set

X 38 Units Lantus X

Case 4: Four Step Calculation 70kg DM1 outpatient 21L and sliding scale with meals with A1c7 1. TDD: 2. Basal: 3. Nutritional: 4. Correction: 40U (21b+21nutr) or (0.5U/kg=35U) 18U Lantus 6U Humalog ac Built into order set The patient is made NPO, how should the insulin dosing be changed? Should a patient with DM1 ever not get basal insulin? Patients with DM1 absolutely require insulin or they will develop DKA.

X 18 Units Lantus X

Case 4 part b: Four Step Calculation 70kg DM1 outpatient 21L and sliding scale with meals with A1c7 1. TDD: 2. Basal: 3. Nutritional: 4. Correction: 40U (21b+21nutr) or (0.5U/kg=35U) 18U Lantus 6U Humalog ac Built into order set POC between 80-100 and steroids tapered. What would you do? 1. TDD: 2. Basal: 3. Nutritional: 4. Correction: 36x0.8=28; 36x0.9=32 15U Lantus 5U Humalog ac Built into order set

X 15 Units Lantus X

Case 5: Four Step Calculation 60kg DM1 insulin pump basal 12 basal and 4 nutritional with A1c8 and unconscious after CVA 1. TDD: 24U (12+12) or (0.4U/kg=24U) 2. Basal: 12U Lantus 3. Nutritional: 4U Humalog ac 4. Correction: Built into order set

X 12 Units Lantus X

Summary Hyperglycemia and Hypoglycemia associated with increased morbidity, mortality, and LOS Four Steps to Calculate Basal Bolus Insulin 1. TDD (calculate: preadmission insulin, weight based, insulin gtt) 2. Basal (~50% TDD) 3. Nutritional (~50% TDD: 60g carb meal) 4. Correction (calculation intrinsic to Order Set)